The effect of hydrophilic statins on adiponectin, leptin, visfatin, and vaspin levels in streptozocin-induced diabetic rats.

Adipokine Diabetes mellitus Pravastatin Rat Rosuvastatin

Journal

Naunyn-Schmiedeberg's archives of pharmacology

ISSN: 1432-1912

Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol

Pays: Germany

ID NLM: 0326264

Informations de publication

Date de publication:
09 Oct 2024

Historique:

received: 21 05 2024

accepted: 04 10 2024

medline: 9 10 2024

pubmed: 9 10 2024

entrez: 9 10 2024

Statut: aheadofprint

Résumé

Statins may affect glucose metabolism through adipokines. The aim of this study was to measure the effects of hydrophilic statins on the levels of several adipokines in diabetic rats. Wistar albino rats were divided into four groups: healthy control, untreated diabetic, diabetic treated with pravastatin, and diabetic treated with rosuvastatin. Diabetes was induced by intraperitoneal injection of STZ. Thereafter, 20 mg/kg/day doses of either pravastatin or rosuvastatin were administered to the treated diabetic rats for 8 weeks. At the end of the experiment, the body weights, fasting blood glucose levels, serum insulin levels, and insulin resistance, as well as the serum adiponectin, leptin, visfatin, and vaspin levels, were measured. Fasting blood glucose and insulin resistance levels were significantly higher, whereas insulin levels and body weight were significantly lower in the untreated diabetic group than in the control group. Diabetes caused significant decreases in adiponectin, leptin, and vaspin levels but a significant increase in visfatin levels. Pravastatin treatment significantly increased body weight and decreased fasting blood glucose levels, whereas rosuvastatin decreased body weight but did not affect fasting blood glucose levels. Pravastatin caused significant increases in both adiponectin and vaspin levels. However, rosuvastatin did not affect the adiponectin level but caused a significant decrease in the vaspin levels. Both pravastatin and rosuvastatin treatments decreased the leptin and visfatin levels. In conclusion, pravastatin is more effective at improving fasting blood glucose levels and body weight in diabetic rats, probably by increasing adiponectin and vaspin levels.

Identifiants

DOI: 10.1007/s00210-024-03517-6 PMID: 39382680

pubmed: 39382680

doi: 10.1007/s00210-024-03517-6

pii: 10.1007/s00210-024-03517-6

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Adams Y, Ofori EK, Asare-Anane H, Amanquah SD, Ababio GK, Abendau E, Nabia R (2018) Adipocytokines in obese Ghanaian subjects with or without type 2 diabetes. BMC Res Notes 11:109–115. https://doi.org/10.1186/s13104-018-3149-4

doi: 10.1186/s13104-018-3149-4 pubmed: 29422086 pmcid: 5806467

Aktaş ŞH, Pençe HH, Özçelik F et al (2020) Vaspin, adiponectin and leptin levels in type 1 diabetic rats induced by streptozotocin. Acta Endocrinol (Buchar) 16(2):136–141. https://doi.org/10.4183/aeb.2020.136

doi: 10.4183/aeb.2020.136 pubmed: 33029228

Al-Azzam SI, Alzoubi KH, Abeeleh JA, Mhaidat NM, Abu-Abeeleh M (2013) Effect of statin therapy on vaspin levels in type 2 diabetic patients. Clin Pharmacol 5:33–38. https://doi.org/10.2147/CPAA.S42496

doi: 10.2147/CPAA.S42496 pubmed: 23449848 pmcid: 3581289

Alexiadou K, Kokkinos A, Liatis S, Perrea D, Katsilambros N, Tentolouris N (2012) Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones 11(4):444-450. https://doi.org/10.14310/horm.2002.1376

Al-Hamodi Z, Al-Habori M, Al-Meeri A, Saif-Ali R (2014) Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr 6(1):99. https://doi.org/10.1186/1758-5996-6-99

doi: 10.1186/1758-5996-6-99 pubmed: 25276234 pmcid: 4177707

Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A (2013) Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 19(27):4904–12

doi: 10.2174/1381612811319270014 pubmed: 23278491

Cheng JX, Yu K (2022) New discovered adipokines associated with the pathogenesis of obesity and type 2 diabetes. Diabetes Metab Syndr Obes 15:2381–2389. https://doi.org/10.2147/DMSO.S376163

doi: 10.2147/DMSO.S376163 pubmed: 35966830 pmcid: 9371465

Dhananjayan I, Kathiroli S, Subramani S, Veerasamy V (2017) Ameliorating effect of betanin, a natural chromoalkaloid by modulating hepatic carbohydrate metabolic enzyme activities and glycogen content in streptozotocin-nicotinamide induced experimental rats. Biomed. Pharmacother 88:1069–1079. https://doi.org/10.1016/j.biopha.2017.01.146

doi: 10.1016/j.biopha.2017.01.146 pubmed: 28192880

Diwan AG, Kuvalakar AA, Dharamsi S, Vora AM, Nikam VA, Ghadje AA (2018) Correlation of serum adiponectin and leptin levels in obesity and type 2 diabetes mellitus. Indian J Endocr Metab 22(1):93–99. https://doi.org/10.4103/ijem.IJEM_491_15

doi: 10.4103/ijem.IJEM_491_15

Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76(1):24–29. https://doi.org/10.1016/j.diabres.2006.07.031

doi: 10.1016/j.diabres.2006.07.031 pubmed: 16956691

Dong C, Wu G, Li H, Qiao Y, Gao S (2024) Type 1 and type 2 diabetes mortality burden: predictions for 2030 based on Bayesian age-period-cohort analysis of China and global mortality burden from 1990 to 2019. J Diabetes Investig 15(5):623–633. https://doi.org/10.1111/jdi.14146

doi: 10.1111/jdi.14146 pubmed: 38265170 pmcid: 11060160

El Samahi MH, Ismail NA, Matter RM, Selim A, Ibrahim AA, Nabih W (2017) Study of visfatin level in type 1 diabetic children and adolescents. Maced J Med Sci 5(3):299–304. https://doi.org/10.3889/oamjms.2017.065

doi: 10.3889/oamjms.2017.065

Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3):357–362. https://doi.org/10.1161/01.cir.103.3.357

doi: 10.1161/01.cir.103.3.357 pubmed: 11157685

Freitas Lima LC, Braga VDA, do Socorro de França Silva M, et al (2015) Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol 6:304. https://doi.org/10.3389/fphys.2015.00304

Gothandam K, Ganesan VS, Ayyasamy T, Ramalingam S (2019) Antioxidant potential of theaflavin ameliorates the activities of key enzymes of glucose metabolism in high fat diet and streptozotocin - induced diabetic rats. Redox Rep. 24(1):41–50. https://doi.org/10.1080/13510002.2019.1624085

doi: 10.1080/13510002.2019.1624085 pubmed: 31142215 pmcid: 6748596

Habeeb NM, Youssef OI, Saab AA, El Hadidi ES (2012) Adiponectin as a marker of complications in type I diabetes. Indian Pediatr 49(4):277–280. https://doi.org/10.1007/s13312-012-0041-5

doi: 10.1007/s13312-012-0041-5 pubmed: 21992860

Hong X, Zhang X, You L, Li F, Lian H, Wang J, Mao N, Ren M, Li Y, Wang C (2023) Sun K (2023) Association between adiponectin and newly diagnosed type 2 diabetes in population with the clustering of obesity, dyslipidaemia and hypertension: a cross-sectional study. BMJ Open 13(2):e060377. https://doi.org/10.1136/bmjopen-2021-060377

doi: 10.1136/bmjopen-2021-060377 pubmed: 36828662 pmcid: 9972409

Hussein MK, Hamza AA, Ahmed AA (2020) Relation between visfatin, body mass ındex with ınsulin resistance in type 2 diabetic Iraqi patients. Univ Thi-Qar J Med 20(2):185–190

Kadoglou NP, Sailer N, Kapelouzou A, Lampropoulos S, Vitta I, Kostakis A, Liapis CD (2012) Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol 49(4):269–276. https://doi.org/10.1007/s00592-011-0310-0

doi: 10.1007/s00592-011-0310-0 pubmed: 21748474

Karamifar H, Habibian N, Amirhakimi G, Karamizadeh Z, Alipour A (2013) Adiponectin is a good marker for metabolic state among type 1 diabetes mellitus patients. Iran J Pediatr 23(3):295–301

pubmed: 23795252 pmcid: 3684474

Kaya Kayhan H, Demirtas B, Yokus B et al (2024) Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model. Acta Pharm 74(1):117–130. https://doi.org/10.2478/acph-2024-0001

doi: 10.2478/acph-2024-0001

Khaled M, Salama RA, Aboughalia A, Tarek M, Mohamed Fawzy N (2024) Apigenin ameliorates genitourinary dysfunction in a type 1 diabetic rat model via Drp1 modulation. Sci Rep 14(1):5754. https://doi.org/10.1038/s41598-024-56395-6

doi: 10.1038/s41598-024-56395-6 pubmed: 38459102 pmcid: 10924091

Khater NM, Abd ELrahman HM, Mohammed RH, Elashery MA (2022) Evaluation of serum visfatin in children and adolescent with type1 diabetes mellitus. Egypt J Hosp Med 86(1):324–328. https://doi.org/10.21608/ejhm.2022.2120225

doi: 10.21608/ejhm.2022.2120225

Ko MJ, Jo AJ, Kim YJ et al (2019) Time-and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: a nationwide observational cohort study. JAHA 8(8):e011320. https://doi.org/10.1161/JAHA.118.011320

doi: 10.1161/JAHA.118.011320 pubmed: 30982384 pmcid: 6507181

Koh KK, Oh PC, Sakuma I, Lee Y, Han SH, Shin EK (2016) Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Int J Cardiol 223:488–493

doi: 10.1016/j.ijcard.2016.08.051 pubmed: 27544612

Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A (2024) Prevalence of diabetes in India: a review of IDF diabetes atlas 10th edition. Curr Diabetes Rev 20(1):105-114. https://doi.org/10.2174/1573399819666230413094200

Kurowska P, Mlyczyńska E, Dawid M, Jurek M, Klimczyk D, Dupont J, Rak A (2021) Vaspin (SERPINA12) expression and function in endocrine cells. Cells 10(7):1710. https://doi.org/10.3390/cells10071710

doi: 10.3390/cells10071710 pubmed: 34359881 pmcid: 8307435

Liu S, Duan R, Wu Y, Du F, Zhang J, Li X, Guo S, Wang M, Zhang Q, Li Y, Li N (2018) Effects of vaspin on ınsulin resistance in rats and underlying mechanisms. Sci Rep 8(1):13542. https://doi.org/10.1038/s41598-018-31923-3

doi: 10.1038/s41598-018-31923-3 pubmed: 30202052 pmcid: 6131547

Lopez-Bermejo A, Chico-Julia B, FernandezBalsells M et al (2006) Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55:2871–2875. https://doi.org/10.2337/db06-0259

doi: 10.2337/db06-0259 pubmed: 17003355

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. https://doi.org/10.1007/BF00280883

doi: 10.1007/BF00280883 pubmed: 3899825

Meek TH, Morton GJ (2016) The role of leptin in diabetes: metabolic effects. Diabetologia 59(5):928–932. https://doi.org/10.1007/s00125-016-3898-3

doi: 10.1007/s00125-016-3898-3 pubmed: 26969486

Min JJ, Shin BS, Lee JH et al (2018) Effects of pravastatin on type 1 diabetic rat heart with or without blood glycemic control. J Diabetes Res 2018:1067853. https://doi.org/10.1155/2018/1067853

doi: 10.1155/2018/1067853 pubmed: 29682576 pmcid: 5850894

Mohammadzadeh G, Zorghami N (2013) Serum leptin levels is reduced in non-obese subjects with type 2 diabetes mellitus. Int J Endocrinol Metab 11(1):3–10. https://doi.org/10.5812/ijem.6535

doi: 10.5812/ijem.6535 pubmed: 23853613

Mostafavinia A, Amini A, Ghorishi SK, Pouriran R, Bayat M (2016) The effects of dosage and the routes of administrations of streptozotocin and alloxan on induction rate of typel diabetes mellitus and mortality rate in rats. Lab Anim Res 32:160–165. https://doi.org/10.5625/1ar.2016.32.3.160

doi: 10.5625/1ar.2016.32.3.160 pubmed: 27729932 pmcid: 5057004

Onyemelukwe OU, Ogoina D, Onyemelukwe GC (2020) Leptin concentrations in type 2 diabetes and non-diabetes Nigerian-Africans. Am J Cardiovasc Dis 10(4):444–454

pubmed: 33224595 pmcid: 7675163

Pilarski Ł, Pelczyńska M, Koperska A, Seraszek-Jaros A, Szulińska M, Bogdański P (2023) Association of serum vaspin concentration with metabolic disorders in obese ındividuals. Biomolecules 13(3):508. https://doi.org/10.3390/biom13030508

doi: 10.3390/biom13030508 pubmed: 36979443 pmcid: 10046748

Sahebkar A, Giua R, Pedone C (2016) Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Clin Pharmacol 82(6):1674–1684. https://doi.org/10.1111/bcp.13086

doi: 10.1111/bcp.13086 pubmed: 27509867 pmcid: 5099545

Salemi Z, Rafie E, Goodarzi MT, Ghaffari MA (2016) Effect of metformin, acarbose and their combination on the serum visfatin level in nicotinamide/streptozocin-ınduced type 2 diabetic rats. Iran Red Crescent Med J 18(3):e23814. https://doi.org/10.5812/ircmj.23814

doi: 10.5812/ircmj.23814 pubmed: 27247792 pmcid: 4884299

Seedevi P, Ramu Ganesa A, Moovendhan M, Mohan K, Sivasankar P, Loganathan S, Shanmugam A (2020) Anti-diabetic activity of crude polysaccharide and rhamnose-enriched polysaccharide from G. lithophila on streptozotocin (STZ)-induced in Wistar rats. Sci Rep 10(1):556. https://doi.org/10.1038/s41598-020-57486-w

doi: 10.1038/s41598-020-57486-w pubmed: 31953455 pmcid: 6969100

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial. Lancet 360(9346):1623–1630

doi: 10.1016/S0140-6736(02)11600-X pubmed: 12457784

Singh P, Zhang Y, Sharma P, Covassin N, Soucek F, Friedman PA, Somers VK (2018) Statins decrease leptin expression in human white adipocytes. Physiol Rep 6(2):13566. https://doi.org/10.14814/phy2.13566

doi: 10.14814/phy2.13566

Sunjaya AP, Sunjaya AF, Halim S, Ferdinal F (2018) Risk and benefits of statins in glucose control management of type II diabetes. Int J Angiol 27(3):121–131. https://doi.org/10.1055/s-0036-1572523

doi: 10.1055/s-0036-1572523 pubmed: 30154630

Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, Kihara S, Caslake MJ, McMahon A, Shepherd J, Funahashi T, Shimomura I (2008) Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 196(1):114–121. https://doi.org/10.1016/j.atherosclerosis.2007.02.013

doi: 10.1016/j.atherosclerosis.2007.02.013 pubmed: 17391675

Tao C, Sifuentes A, Holland WL (2014) Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes. Best Pract Res Clin Endocrinol Metab 28(1):43–58. https://doi.org/10.1016/j.beem.2013.11.003

doi: 10.1016/j.beem.2013.11.003 pubmed: 24417945

Taşdemir E, Sermet A (2019) The relationship between plasma adipsin, adiponectin, vaspin, visfatin, and leptin levels with glucose metabolism and diabetes parameters. Haydarpasa Numune Med J 59(2):95–103. https://doi.org/10.14744/hnhj.2019.62534

doi: 10.14744/hnhj.2019.62534

von Eynatten M, Schneider JG, Hadziselimovic S, Hamann A, Bierhaus A, Nawroth PP, Dugi KA (2005) Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 28(3):754–755. https://doi.org/10.2337/diacare.28.3.754

doi: 10.2337/diacare.28.3.754

Wanders D, Plaisance EP, Judd RL (2010) Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes 1(4):116–128. https://doi.org/10.4239/wjd.v1.i4.116

doi: 10.4239/wjd.v1.i4.116 pubmed: 21537437 pmcid: 3083894

Wauters M, Considine RV, Van Gaal LF (2000) Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 143(3):293–311. https://doi.org/10.1530/eje.0.1430293

doi: 10.1530/eje.0.1430293 pubmed: 11022169

Werida R, Khairat I, Khedr NF (2021) Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomed Pharmacother 135:111179. https://doi.org/10.1016/j.biopha.2020.111179

doi: 10.1016/j.biopha.2020.111179 pubmed: 33401219

Werida R, Khedr L, El-Sisi AE, Salama M (2018) Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD. Curr Res Cardiol 5:26–29

doi: 10.4172/2368-0512.1000107

Xilifu D, Tuerxun Z, Nuermaimaiti B, Aili A, Rehemu N, Sun H, Zhang X (2022) Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats. BMC Pharmacol Toxicol 23(1):66

doi: 10.1186/s40360-022-00595-1 pubmed: 36064644 pmcid: 9442931

Yanai H, Yoshida H (2019) Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci 20(5):1190. https://doi.org/10.3390/ijms20051190

doi: 10.3390/ijms20051190 pubmed: 30857216 pmcid: 6429491

Zhou Z, Curtis AJ, Ernst ME et al (2022) Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. Eur J Clin Pharmacol 8:467–476. https://doi.org/10.1007/s00228-021-03239-1

doi: 10.1007/s00228-021-03239-1